Analysts at Societe Generale Kept the Same their Sell rating for GlaxoSmithKline PLC (LON:GSK) with GBX 1130.00 Target Price; Harvey Partners Has Boosted By $2.38 Million Its Intel (INTC) Position

March 14, 2018 - By Peter Erickson

Harvey Partners Llc increased Intel Corp (INTC) stake by 104.17% reported in 2017Q3 SEC filing. Harvey Partners Llc acquired 62,500 shares as Intel Corp (INTC)’s stock declined 2.96%. The Harvey Partners Llc holds 122,500 shares with $4.67 million value, up from 60,000 last quarter. Intel Corp now has $242.33B valuation. The stock increased 0.50% or $0.26 during the last trading session, reaching $51.78. About 45.57M shares traded or 26.48% up from the average. Intel Corporation (NASDAQ:INTC) has risen 19.47% since March 14, 2017 and is uptrending. It has outperformed by 2.77% the S&P500.

In a note revealed to clients on 14 March, GlaxoSmithKline PLC (LON:GSK) stock Sell was reaffirmed by Societe Generale. They currently have a GBX 1130.00 target price on the stock. Societe Generale’s target price suggests a potential downside of -14.22% from the company’s current price.

Since October 2, 2017, it had 0 insider buys, and 19 sales for $34.96 million activity. $66,959 worth of Intel Corporation (NASDAQ:INTC) was sold by RENDUCHINTALA VENKATA S M on Wednesday, February 7. Krzanich Brian M sold $144,706 worth of stock. Shenoy Navin also sold $35,262 worth of Intel Corporation (NASDAQ:INTC) shares. The insider Bryant Diane M sold $67,048. Shares for $31,943 were sold by McBride Kevin Thomas on Wednesday, February 21. On Monday, October 30 YOFFIE DAVID B sold $1.35 million worth of Intel Corporation (NASDAQ:INTC) or 30,000 shares. Smith Stacy J had sold 472,337 shares worth $20.89M.

Investors sentiment decreased to 1.02 in 2017 Q3. Its down 0.01, from 1.03 in 2017Q2. It is negative, as 52 investors sold INTC shares while 663 reduced holdings. 127 funds opened positions while 608 raised stakes. 3.05 billion shares or 0.19% more from 3.05 billion shares in 2017Q2 were reported. Regal Invest Advisors Llc invested in 21,288 shares or 0.19% of the stock. Grassi Investment Mgmt owns 117,341 shares or 0.75% of their US portfolio. Moreover, Winslow Evans Crocker has 0.58% invested in Intel Corporation (NASDAQ:INTC) for 45,706 shares. Raymond James Assoc has invested 0.31% in Intel Corporation (NASDAQ:INTC). Alphaone Investment Svcs Limited Liability Company holds 964 shares or 0.01% of its portfolio. Tci Wealth Advisors holds 0.42% or 22,756 shares. Central National Bank & Tru has 18,402 shares for 0.17% of their portfolio. City Hldgs holds 1.34% or 104,939 shares in its portfolio. Bahl And Gaynor holds 0.44% or 1.05 million shares in its portfolio. Vista Capital Prtn stated it has 25,498 shares or 0.23% of all its holdings. Reynders Mcveigh Cap Management Ltd reported 109,537 shares. Winfield Assocs has invested 0.09% of its portfolio in Intel Corporation (NASDAQ:INTC). The Washington-based Huntington Steele Ltd Co has invested 0.13% in Intel Corporation (NASDAQ:INTC). 48,225 are owned by 1832 Asset Management Ltd Partnership. Chatham Cap, a Georgia-based fund reported 13,477 shares.

Among 54 analysts covering Intel Corporation (NASDAQ:INTC), 36 have Buy rating, 5 Sell and 13 Hold. Therefore 67% are positive. Intel Corporation had 227 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Positive” rating given on Tuesday, September 20 by Susquehanna. The rating was maintained by Nomura on Wednesday, October 19 with “Buy”. CLSA initiated the shares of INTC in report on Tuesday, May 17 with “Underperform” rating. As per Friday, January 26, the company rating was maintained by RBC Capital Markets. On Friday, October 20 the stock rating was maintained by Roth Capital with “Buy”. The rating was maintained by Morgan Stanley on Friday, January 26 with “Equal-Weight”. The stock of Intel Corporation (NASDAQ:INTC) earned “Hold” rating by SunTrust on Friday, January 26. The company was maintained on Wednesday, October 19 by Citigroup. Canaccord Genuity maintained the stock with “Buy” rating in Monday, August 31 report. Stifel Nicolaus maintained Intel Corporation (NASDAQ:INTC) on Thursday, July 27 with “Buy” rating.

The stock increased 0.17% or GBX 2.26 during the last trading session, reaching GBX 1318.66. About 1.54 million shares traded. GlaxoSmithKline plc (LON:GSK) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of 64.51 billion GBP. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 42.54 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.